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Abstract
microRNAs (miRs) are small non-coding RNAs that 
regulate both mRNA and protein expression of target 
genes, which results in alterations in mRNA stability or 
translation inhibition. miRs influence at least one third 
of all human transcripts and are known regulators of 
various important cellular growth and differentiation 
factors. miRs have recently emerged as key regulatory 
molecules in chronic liver disease. This review details 
recent contributions to the field of miRs that influence 
liver development and the broad spectrum of disease, 
from non-alcoholic fatty liver disease to fibrosis/cirrho-
sis, with particular emphasis on hepatic stellate cells 
and potential use of miRs as therapeutic tools. 
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INTRODUCTION
Post-transcriptional regulation of  gene expression in-
volves numerous modifications to the mRNA, including 
alterations at both 5’ and 3’ ends in addition to splicing 
of  the transcripts. The 3’ untranslated regions (UTRs) of  
mRNAs contain key stability elements that are subject to 
various regulatory proteins, as well as microRNA (miR) 
binding sites. miRs are small non-coding RNAs that alter 
gene expression through perfect complementarity of  the 
miR to the target sequence, which results in mRNA insta-
bility and subsequent endonucleolytic cleavage or alternate 
5’ modifications[1]. Imperfect base pairing with the 3’ UTR 
of  target mRNA results in gene translation inhibition[2]. 
Research focusing on miR modes of  action has primarily 
examined interactions with the 3’ UTR of  target genes; 
however, recent studies have expanded our knowledge and 
have demonstrated that miRs can interact with the 5’ UTR 
as well as interact with DNA methylation machinery and 
affect chromatin status[3]. Since their discovery in 1993, 
miRs have been described in all multicellular organisms 
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and are associated with a vast breadth of  biological func-
tions including proliferation, cellular differentiation and 
immunity, as well as tissue remodeling and various human 
disease states, notably cancer[4]. Although much remains 
to be learned, miRs have already been shown to influence 
the expression of  many mRNAs and proteins that are im-
portant in liver homeostasis in health and disease (Table 1). 
Emerging roles for miRs in liver development and disease 
are discussed in this review, as well as their potential for 
clinical application. 
miRs IN LIVER DEVELOPMENT AND 
DISEASE
Liver development
miRs, while currently being exploited to understand dis-
ease pathologies, have been less appreciated in the role of  
functional gene repression during cellular growth and liver 
development. miRs, specifically let 7 and lin4, control lar-
val development transition in Caenorhabditis elegans, as well 
as apoptotic pathways and growth in Drosophila[5]. Recent 
studies have elegantly demonstrated that miRs regulate 
differentiation of  human cells and development of  whole 
organ systems, which shows tissue-specific expression. miR 
122 accounts for approximately 70% of  the total liver miR 
population; however, specific roles for this miR outside of  
disease-associated functions [e.g. hepatitis C virus (HCV) 
and hepatocellular carcinoma (HCC)] are less clear, espe-
cially with regard to normal liver development. Xu et al[6] 
have shown that miR 122 is strongly upregulated during 
liver embryonic development with expression correlative 
to liver enriched transcription factors (LETFs) C/EBPα, 
HNF1α and HNF3 isoforms, which are all necessary for 
proper hepatocyte development and function. Addition-
ally, the transcriptional repressor CUTL1, which is known 
to promote proliferation and suppress differentiation, is 
gradually repressed by miR 122 during development. In vitro 
miR 122 knockdown experiments have shown restoration 
of  CUTL1 expression and of  downstream target genes, 
which emphasizes that, during development, miR 122, as 
an effector molecule of  LETFs, regulates a delicate balance 
between differentiation and proliferation[6]. Quantitative 
analysis of  miRs in fetal vs adult livers has demonstrated 
that miR expression levels are higher in the fetal period 
and expression levels during this time are dynamic[5]. Ad-
ditionally, recent studies have demonstrated that 162 miRs 
exhibit tissue-specific distribution in mice[7]. Endoderm-
derived liver, jejunum and pancreas display differential miR 
enrichment, with miRs 122, 21, 101b, 107, 192 and 221 
among those with the highest reads per million concentra-
tions. Additionally, mapping of  transcriptional start sites 
has demonstrated that divergent sites are used by miRs in 
endoderm-derived liver tissue as opposed to stem cells. Ma-
ternal influences on miR expression have also been identi-
fied and may be affected by diet. For example, studies by 
Zhang et al[8] have shown that, as a result of  maternal high-
fat diet, expression of  miR let 7c is decreased in offspring, 
along with 23 other miRs including 122 and 194. let 7c was 
identified by Tzur et al[9] as being highly expressed in adult 
compared to embryonic liver, and that profibrotic trans-
forming growth factor-β receptor 1 is a target of  this miR. 
The miR 30 family has recently been shown to be crucial 
for liver development, because it is upregulated during later 
stages that influence known regulators of  hepatic function, 
including epidermal growth factor receptor. GW182, a 
crucial component in miR-mediated gene repression, is also 
a target of  this miR family, which indicates a more global 
role for miRs in earlier stages of  epigenetic silencing via the 
RNA-induced silencing complex[10]. Functional analyses in 
zebrafish larvae have demonstrated that biliary morpho-
genesis is under the regulation of  miR 30a, as knockdown 
studies have resulted in defective bile duct excretion[11]. The 
liver, as a vital multifunctional organ, must maintain proper 
epigenetic programming to ensure xenobiotic and bile me-
tabolism, and vitamin and glucose storage among a plethora 
of  other tasks, which emphasizes the importance of  proper 
cellular differentiation and development.
Nonalcoholic fatty liver disease/nonalcoholic 
steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) is character-
ized by hepatic fat accumulation without significant alcohol 
consumption or other underlying etiology[12]. NAFLD in-
cidence is rising as a result of  the increased population of  
obese individuals worldwide, with severity of  the disease 
ranging from steatosis/steatohepatitis (NASH) to cirrhosis. 
Although most patients with NAFLD are asymptomatic, 
clinical manifestations of  the disease are well described and 
include hyperechoic appearance of  the liver on ultrasound, 
dyslipidemia, systemic arterial hypertension, and insulin re-
sistance. Although disease pathogenesis is not completely 
understood, recently, a role for miRs in NAFLD has been 
established[13]. Lipid droplet accumulation in hepatocytes as 
a marker of  steatosis is associated with various liver diseas-
es including NAFLD. Recent high-content screening stud-
ies have shown that 11 miRs are able to alter lipid droplet 
formation/retention[14]. Specifically, miR 181d decreased 
droplets by approximately 60%, which subsequently re-
duced cellular triglycerides and cholesterol. Peroxisome 
proliferator-activated receptor (PPAR)α, a major contribu-
tor to NAFLD pathogenesis, has recently been identified 
as a target of  miR 10b, which has been shown to regulate 
steatosis level in L02 cells (steatotic hepatocyte model)[15]. 
Additionally, post-transcriptional regulation of  PPARα by 
miR 10b is maintained by a single binding site, as demon-
strated by mutation analyses. NASH can progress to end-
stage cirrhosis in approximately 15% of  patients, with 
the mechanism that underlies disease progression being 
undefined. Recent studies in humans have demonstrated 
that miR expression profiles are altered in NASH. Unsur-
prisingly, miR 122 is significantly underexpressed (63%) in 
NASH subjects compared to those without the metabolic 
syndrome[16]. Overexpression of  miR 122 in HepG2 cells 
results in a significant decrease in sterol regulatory ele-
ment binding proteins (SREBP1-c, SREBP2), FAS and 
3-hydroxy-3-methyl-glutaryl-CoA reductase; all of  which 
are key lipogenic genes in human NASH. Lesser known 
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miRs 34a and 146b are significantly overexpressed (99 and 
80%, respectively) in NASH. In a smaller sample study (n 
= 12/group), seven miRs have been found to be differen-
tially expressed, including 132, 150, 197 and 99; the latter 
two are significantly associated with pericellular fibrosis[17]. 
It is of  particular importance to note that previous studies 
have shown that miR signatures change in accordance with 
disease stage and source of  hepatic injury (ethanol or high 
fat diet)[18,19]. These studies emphasize the importance of  
avoiding generalization when examining miRs as potential 
biomarkers, because miR expression patterns of  end-stage 
disease may be similar but expression profiles that lead to 
organ dysfunction appear to be divergent. 
Viral infection 
Along with NASH, HCV is one of  the most common global 
causes of  hepatic fibrosis and cirrhosis. According to the 
World Health Organization, over 180 million people are 
infected with the single-stranded RNA virus, with > 70% of  
that population at risk for developing cirrhosis[20]. Pegylated 
interferons in conjunction with ribavirin have improved 
treatment of  chronic hepatitis C; however, a large percent-
age of  the infected population remains unresponsive to 
available regimens, which emphasizes the need to better 
understand the mechanisms of  cellular infection, for devel-
opment of  novel drug therapies. Numerous studies have 
emphasized a role for miR 122 in several aspects of  hepatic 
function and disease, including HCV replication[21]. Plasma 
levels of  miR 122 are elevated in hepatitis B virus (HBV)- 
and HCV-infected patients, as well as in models of  alcohol 
and drug-induced liver damage reinforcing a role for miRs 
as biomarkers[22]. However, recent studies by Ura et al[23] 
have shown that miR expression patterns are divergent in 
HBV- and HCV-infected livers. Additionally, elegant stud-
ies by Hou et al[24] have demonstrated that miR 196 directly 
acts on the 3’UTR of  Bach1, the transcriptional repressor 
of  heme oxygenase 1, a critical cytoprotective enzyme. 
This miR also inhibits HCV expression (both genotype 1b 
and 2a) in human hepatocytes in vitro, which shows clinical 
promise. Accordingly, parallel miR and mRNA expression 
profiling studies in genotype-1b-expressing cells have shown 
numerous anti-correlated miR/mRNA pairs affected by the 
presence HCV[25]. Among the noted anti-correlated pairs 
that have been detected in a human cell line that expresses 
the HCV Con1 replicon, miR 130a/b is correlated with de-
creased PPARγ expression, which is a known regulator of  
the quiescent hepatic stellate cell (HSC) profile. Additional 
miR/mRNA profiling in HCV-infected hepatoma cells 
has shown a total of  108 differentially expressed miRs, and 
among this pool, miRs 24, 149, 638 and 1182 are predicted 
to control HCV entry, replication and viral propagation[26]. 
Scagnolari et al[27] have examined miR expression in periph-
eral blood mononuclear cells from healthy and chronic-
HCV-infected patients and have found that miRs 1, 30, 128, 
196 and 296 are differentially expressed and that treatment 
with interferon (IFN)α induces all aforementioned miRs. 
Although limited by small sample size, baseline levels of  
miRs do not appear to differ significantly between respond-
ers and non-responders; however, expression of  miRs 128 
and 196 appears higher in the responsive population. Addi-
tionally, Pedersen et al[28] have demonstrated this same set of  
miRs, which possess sequence-predicted targets within HCV 
genomic RNA, and are induced by IFNβ stimulation. The 
tumor suppressor gene DLC-1 (deleted in liver cancer-1) 
is also a target of  miR repression[29]. Levels of  DLC-1 are 
decreased in HCV-infected cells, which are correlated with 
the increase in miR 141. Depletion of  this miR inhibits viral 
replication, while addition of  exogenous miR 141 increases 
replication rates, which indicates that miR regulation of  tu-
mor suppressor genes can influence HCV infection and play 
a role in HCC development (for a comprehensive review of  
miRs in HCC see[30,31]). 
Alcoholic liver disease
Alcoholic liver disease (ALD) is a major healthcare burden 
worldwide and a leading cause of  liver-related mortality. It 
is well known that ethanol consumption alters methylation 
status and other epigenetic factors, including histone tail 
signatures, signal transduction pathways and transcription 
factor expression. Ethanol metabolism affects chromatin 
condensation, which results from direct DNA methyla-
tion or histone protein alterations (acetylation, methylation 
or phosphorylation)[32]. Additionally, DNA methylation is 
connected to direct interference by small RNAs[33]. There-
fore, it is plausible that, as a result of  epigenetic remod-
eling, ethanol exposure can also alter miR expression. 
Ethanol has been shown to repress miRs 9, 21, 153 and 
335 in neural stem cells and neural progenitor cells that 
alter cellular development and maturation[34]. Additionally, 
miR 21 influences PTEN/PI3K signaling, which ulti-
mately contributes to the fibrotic response, and both miRs 
9 and 335 are predicted (by TargetScan) to bind to targets 
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Table 1 Differentially expressed microRNAs in liver development and disease
Liver status Upregulated miRs Downregulated miRs Ref.
Development 122, 92a, 483, 486-5p, 30 family 22, let 7 family, 199a, 21 [6,21]
NASH/NAFLD 34a, 146b, 200a, 224, 222, 10b, 22, 33, 31, 29c 122, 181d, 132, 150, 28-3p, 511, 517a, 671-3p, 99b, 433 [14-16]
HCV 122, let 7f, 155, 146, 296, 351, 128, 296, 141 196, 15a, 15b, 17, 106a, 106b, 181a, 29a, 29b, 93, 310, 30a, 30c, 24, 221, 222 [24,26,27]
ALD 705, 1224, 212 182, 183, 199a-3p, 199, NSC/NPC: 9, 21, 153, 335 [18,34]
Fibrosis 125-5p, 199b, 221, 302c, 223, 34c, 24 29a, 29b, 29c, 30b, 30c, 183, 96, 877, 341, 193, 132 [40,42]
Regeneration 21, 130a, 181b, 20a, 20b 378, 689, 7 [48,49]
NSC: Neural stem cell; NPC: Neural progenitor cell; miRs: microRNAs; HCV: Hepatitis C virus; ALD: Alcoholic liver disease; NAFLD: Nonalcoholic fatty 
liver disease; NASH: Nonalcoholic steatohepatitis.
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that influence the progression of  ALD[35]. Previous stud-
ies have highlighted the importance of  miRs in the gut-
liver axis and have shown that ethanol exposure alters miR 
profiles in liver cells[36]. Specifically, endotoxemia and direct 
ethanol exposure modulate hepatic miRs 182, 183, 705, 
1224 and 199a-3p[37]. Symptomatic of  ALD, hepatic mi-
crocirculation is disrupted when increased portal pressure 
arises as a result of  altered endothelin-1 (ET-1) expression, 
with subsequent increases in NADPH oxidase and hypoxia 
inducible factor-1α[38]. Recent studies have shown that miR 
199 is involved in ET-1 expression in rat liver sinusoidal 
endothelial cells and human endothelial cells, by function-
ing as a negative regulator of  ET-1 transcription and thus 
vascular tone in ALD[39]. For still unknown reasons, only 
20%-30% of  chronic heavy alcohol users develop hepatic 
fibrosis. Future studies of  miRs involved in ALD may al-
low us to uncover additional factors that contribute to the 
disparity that exists in disease development.
Liver fibrosis
Commonalities of  miR expression can also be seen among 
fibrotic disorders of  different organ systems, including 
cardiac and renal fibrosis, with an overarching effect of  the 
miR 29 family in regulation of  effector cellular differentia-
tion or in translation of  extracellular matrix (ECM) com-
ponents[35]. Additionally, miRs involved with translation of  
profibrotic transforming growth factor (TGF)β/SMAD 
signaling are shared amongst pathologies. Roderburg et al[40] 
have examined miR expression profiles in a CCl4 rodent 
model of  hepatic fibrosis, and microarray analyses have 
revealed 31 differentially expressed miRs; 10 of  which are 
overexpressed in fibrotic tissue, including miRs 125-p, 199b, 
221 and 302c. Marked downregulation has been observed 
in a pool of  21 miRs; specifically, miR 29 family members 
were significantly reduced. Additional experiments in an 
alternate model of  fibrosis (bile duct ligation; BDL) have 
confirmed that miRs 29b/c are significantly reduced com-
pared to sham controls. Downregulation of  miRs 29a/b/c 
could also be observed in explanted liver samples with 
patients denoted by a Desmet fibrosis score of  2-4. Low 
plasma levels of  miR 29a correlate with advanced stage liver 
fibrosis in human patients. The idea that low miR levels in 
the tissue correlate with low miR in the circulating plasma 
is in opposition to recent hypotheses that an inverse cor-
relation between tissue and plasma miR concentrations ex-
ists as a byproduct of  vesicles that release miRs[41]. Hepatic 
fibrosis is influenced by several epigenetic factors that con-
trol the wound-healing response. Recent studies by Mann 
et al[42] have shown that miR 132 is significantly decreased in 
fibrotic livers as demonstrated in two different models (BDL, 
CCl4), and this downregulation influences HSC activation. 
Collectively, these studies have emphasized that, during de-
velopment of  fibrosis, there are important changes in miR 
expression that regulate wound-healing transcripts; how-
ever, effects exerted by miRs appear to act in concert with 
other epigenetic factors to direct disease progression. 
miRs IN HSCs
HSCs are the main effector cell population in hepatic fi-
brosis as the primary source of  typeⅠ collagen deposition 
following injury. Injury from several sources, including 
viral infection, obesity and alcohol consumption, causes 
activation of  HSCs, in which quiescent lipid-rich cells 
transdifferentiate into fully activated myofibroblasts. The 
activated form of  the HSC secretes profibrogenic media-
tors, including TGFβ, and generates ECM components 
including fibrillar collagens, fibronectin and laminin, which 
exacerbates the wound-healing process[38]. Recent studies 
have shown that miRs are involved in HSC transdiffer-
entiation (Figure 1). Specifically, miRs 150, 187, 194 and 
207 are significantly downregulated in HSCs isolated from 
BDL animals compared to sham controls, whereas let 7 
family members are significantly upregulated[43]. Overex-
pression of  miRs 150 and 194 in human HSCs (LX-2) 
results in proliferation inhibition as well as decreases in 
type Ⅰ collagen and smooth muscle alpha actin (αSMA), 
which are hallmarks of  HSC activation. Specific action of  
these two miRs includes inhibition of  c-Myb and Ras-re-
lated C3 botulinum toxin substrate 1 (Rac-1), which both 
contribute to development and progression of  fibrosis. 
Additional studies have examined differential expression 
in quiescent (day 2) and activated (day 14) rat HSCs, and 
have shown 12 upregulated and nine downregulated miRs, 
of  which, 15b, 16, 122, 138, 140 and 143 have been vali-
dated[44,45]. Gene ontology has revealed specific linkages 
between the miR 15/16 family and anti-apoptotic path-
ways that are important in HSC activation. Administration 
of  miR mimics induced Bcl-2 inhibition and subsequent 
apoptosis in the activated HSCs, an important aspect of  
potential therapeutic targeting. Additional studies by Guo 
et al[44] have further demonstrated that lentiviral delivery of  
miR 16 greatly reduces cyclin D1 levels in addition to in-
hibiting proliferation and increasing apoptosis in activated 
HSCs. More recent studies by Ogawa et al[46] have shown 
2539 May 28, 2011|Volume 17|Issue 20|WJG|www.wjgnet.com
Figure 1  microRNAs involved in hepatic stellate cell transdifferentia-
tion. Functional manipulation studies utilizing mimics and/or antagomirs have 
demonstrated that the miRs depicted in the above schematic regulate key 
genes/functions in hepatic stellate cells (HSCs). (Quiescent HSC: yellow circles 
represent cytoplasmic lipid droplets; activated HSC: purple lines indicate cyto-
skeletal protein smooth muscle alpha actin; green oval represents Bcl-2; red 
fibrils represent collagen). Additional profiling studies have shown upregulation 
of several microRNAs (miRs) in both phenotypes, some of which are already 
associated with hepatic disease (boxes contain a small fraction of published 
miRs). References[38-43,47] were used to generate the contents of this figure with 
design software BioDraw Ultra 12.0.
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that TGFβ1 or IFNα stimulation validate in silico analyses 
of  miR-pro-collagen [Colα1 (Ⅰ)] mRNA binding sites. 
miRs 29b, 143 and 218 demonstrate the highest degree 
of  homology to the Colα1 (Ⅰ) 3’UTR and have been 
further analyzed. miR 29b directly bound to the 3’UTR 
suppresses type Ⅰ collagen at the mRNA and protein lev-
els. Potential antifibrotic benefit to miR 29b has also been 
validated in vivo using a murine CCl4 model of  injury (see 
Liver fibrosis section). In vitro studies conducted by Roder-
burg et al[40] have also shown that overexpression of  miR-
29b in murine HSCs results in decreased collagen expres-
sion and that lipopolysaccharide and nuclear factor (NF)κB 
are involved in downregulation of  this miR. The process 
of  HSC activation includes the methyl CpG binding pro-
tein MeCP2 and constituents of  the polycomb repressive 
complex. More recently, miR 132 has been shown to ac-
tivate this epigenetic pathway because its downregulation, 
observed in fibrotic livers, permits translation of  MeCP2, 
which is subsequently recruited to the 5’ end of  PPARγ, 
and through altered methylation patterns, it confers sup-
pression of  the quiescent profile[42]. Previously studies by 
Ji et al[47] showed miRs 27a and b are upregulated during 
activation and directly repress RXRalpha. Inactivation of  
these miRs in vitro showed partial reversion of  the cell to 
a quiescent phenotype with restoration of  lipid droplet 
accumulation. Improved understanding of  the regulation 
of  HSC activation by miRs will undoubtedly advance our 
knowledge of  many liver etiologies. 
miRs IN LIVER REGENERATION 
As a result of  hepatic injury, hepatocytes are capable of  
undergoing multiple divisions, and in the case of  partial 
(2/3) hepatectomy (PH), liver mass is restored within 
7 d[48]. Liver regeneration is a complex process that involves 
intricate cytokine and growth factor signaling influencing 
cell cycle progression. Recent studies have begun to exam-
ine the role of  miRs in this process, to uncover underlying 
mechanisms that may be manipulated to ensure rapid tissue 
repair. miR-deficient mice (DGCR8 inactivated) that have 
undergone PH are clearly delayed in cell cycle progres-
sion; specifically G1 to S phase transition[48]. Examination 
of  differentially expressed miRs in wild-type mice has re-
vealed marked induction of  miR 21 at 18 h post-PH, and 
downregulation of  miR 378. These studies also have shown 
that miR 21 targets cell cycle inhibitor B cell translocation 
gene 2 (Btg2), which prevents DNA synthesis in hepato-
cytes, whereas miR 378 inhibits ornithine decarboxylase 
(Odc1), a promoter of  DNA synthesis. Studies by Castro 
et al[49] have confirmed that miR 21 expression is increased 
following PH, and can be modulated by ursodeoxycholic 
acid (UDCA), a pro-survival agent in hepatic regenera-
tion. miR profiles from rats that have undergone 70% PH 
have shown that miR 21 levels are highest at 24, 36 and 
72 h post-hepatectomy. Inhibition of  this miR reduces 
hepatocyte proliferation and increases levels of  lactate de-
hydrogenase. UDCA treatments increase miR 21 as well as 
several others, including 143 and 151, which points towards 
a mechanism of  action of  the compound. As previously 
noted, miR 21 has been shown to repress PTEN signaling, 
the negative repressor of  the AKT pathway that is neces-
sary for hepatic regeneration. Additional experiments with 
miR 21 have shown that it is upregulated in early stages of  
regeneration and its overexpression inhibits NF-κB signal-
ing[50]. Although the miR signature following 50% PH is 
slightly distinct from published data on 2/3 PH, miR 21 as 
well as miRs 22a, 26a, 30b and members of  the let 7 family, 
which are already known to play a role in hepatic tissue de-
velopment, are also differentially expressed[51]. Although key 
regulatory factors that govern organ regeneration are most-
ly unknown, recent studies in zebrafish have shown that 
suppression of  miRs 133 and 203 is required for append-
age regeneration; however, this process is mediated by stem 
cells in contrast to fully differentiated hepatocytes that are 
necessary to regenerate mammalian liver tissue. Enhanced 
knowledge of  miRs that regulate hepatocyte proliferation 
following PH may also allow restoration of  this function in 
diseased parenchymal cells[48]. 
CLINICAL APPLICATION OF miRs
Currently, there are no established FDA-approved treat-
ments for hepatic fibrosis. Outside of  surgical resection, 
full organ transplantation is an option for certain disease 
states; however, the current list of  patients in need of  trans-
plant far exceeds the annual donor rate. As is always the 
case, the clinical applications of  new discoveries, such as 
the existence and manifold roles of  miRs in liver physiol-
ogy and pathophysiology, lag behind the laboratory-based 
discoveries summarized above. Thus, currently, profiles of  
miRs and creation of  miRs in various liver diseases, and the 
use of  alterations in these as prognostic indicators or for 
categorization of  liver diseases, have not been introduced 
into routine clinical practice. Nevertheless, it seems likely 
that, within the next 3-5 years, some centers and physicians 
will begin to use miR profiling to help categorize patients at 
higher or lower risk of  adverse outcomes, especially from 
acute liver diseases, such as drug- or toxin-induced injury 
or fulminant liver failure of  any cause. Another likely ap-
plication will be the profiling of  miR expression in hepatic 
tumors as an aid to prognosis, and perhaps, to help guide 
therapeutic decisions. However, it seems unlikely that such 
profiling will become generally available for widespread 
clinical application within the next 10 years, because many 
more studies with large numbers of  subjects will be needed, 
with demonstration that such specialized profiling offers 
clear advantages in improving outcomes at reasonable and 
justifiable incremental costs.
What seems more likely is that therapy directed at in-
fluencing the hepatic levels of  selected miRs such as miR 
122, already shown to play an important role in affecting 
levels of  serum cholesterol and levels of  the HCV, both 
in cell culture[52,53] and chimpanzee models[54], will find a 
place in clinical therapeutics. Indeed, phase 2 clinical stud-
ies of  locked nucleic acids that downregulate miR 122 
expression are already in progress, and results of  these are 
awaited with great interest. Similarly, therapeutic altera-
tion of  miR 196[24] and, in future, other miRs seems likely 
also to be pursued. However, we must also keep in mind 
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the high costs and lengthy duration usually needed for ap-
provals of  all new drugs. Also, the unwanted side effects 
of  such treatments may limit their clinical application.
CONCLUSION 
Thus, at this juncture, miRs are clearly more than just the 
latest fad. They are important and fundamental modula-
tors of  mRNA and protein expression. In future, pur-
poseful modulation of  these levels and effects will, more 
likely than not, become important in the therapeutic 
armamentarium of  hepatic and other diseases. Although 
the clinicopathological and prognostic value of  miRs re-
mains highly anticipated, further exploration into systemic 
effects of  miR modulation, both endogenously and exog-
enously, is needed, as well as a deeper understanding of  
miR biogenesis in both the development and progression 
of  liver diseases. 
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